Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweetsMarketScreener Strategies

Allergan says revenue from aesthetics unit may double by 2025

share with twitter share with LinkedIn share with facebook
share via e-mail
09/14/2018 | 07:49pm CET
The Allergan logo is seen in this photo illustration

NEW YORK (Reuters) - Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

The drugmaker announced earlier on Friday the acquisition of Bonti Inc, which makes a shorter-acting neurotoxin than Botox.

Allergan is also doubling its investment in direct-to-consumer ad spending and beefing up its sales force as companies like Revance Therapeutics Inc and Evolus Inc vie to wrest market share with rival treatments to Botox. The company made the announcements at its Medical Aesthetics Day in New York.

Chief Commercial Officer Bill Meury said Allergan expects revenue at its medical aesthetics unit to grow to $7 billion to $8 billion. That compares with revenue of $3.8 billion from the business in 2017.

Beyond Botox, the unit includes dermal filler Juvederm, the CoolSculpting fat-freezing systems, and other treatments.

He said the forecast implied an 8 to 10 percent compound annual growth rate.

Meury said the Bonti acquisition would allow the company to market a new "starter toxin." Patients could test drive the treatment, which lasts for two to four weeks, to help them decide if they want to use longer-term Botox.

Shares of Allergan fell 0.9 percent to $188.21 on Friday, while shares of Revance were down 1.1 percent and Evolus fell around 2.5 percent.

(The story corrects Allergan company stock price in final paragraph.)

(Reporting by Michael Erman; Editing by Chizu Nomiyama and Bernadette Baum)

By Michael Erman

Stocks mentioned in the article
ChangeLast1st jan.
ALLERGAN PLC -1.47% 157.03 Delayed Quote.-3.58%
EVOLUS INC 0.00% 14.6 Delayed Quote.0.00%
REVANCE THERAPEUTICS INC 0.38% 21.01 Delayed Quote.-41.29%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
11/15ALLERGAN PLC : Entry into a Material Definitive Agreement, Financial Statements ..
11/14Pfizer loses drug patent fight in UK top court, may face claims
11/13ALLERGAN PLC : Entry into a Material Definitive Agreement, Financial Statements ..
11/10ALLERGAN : Dr. Justin Harper and Sam Peck Selected For Allergan Medical Spa Advi..
11/09ALLERGAN PLC : Ex-dividend day for
11/08ALLERGAN : Form of prospectus disclosing information, facts, events covered in b..
11/05ALLERGAN : to Present at Credit Suisse 27th Annual Healthcare Conference
11/01Pfizer weighing sale of women's health portfolio - Bloomberg
11/01ALLERGAN PLC : Regulation FD Disclosure, Financial Statements and Exhibits (form..
10/31ALLERGAN : Quarterly report which provides a continuing view of a company's fina..
More news
News from SeekingAlpha
11/14Tracking Seth Klarman's Baupost Group Holdings - Q3 2018 Update 
11/14ClearBridge International Value Strategy Portfolio Manager Commentary Q3 2018 
11/14Pfizer loses Lyrica patent fight 
11/13ALDER BIOPHARMACEUTICALS : Pure Play Migraine Prevention Treatment In A Crowded .. 
11/13Express Scripts launches new formulary aimed at reducing drug costs 
Financials ($)
Sales 2018 15 679 M
EBIT 2018 7 493 M
Net income 2018 -1 066 M
Debt 2018 22 216 M
Yield 2018 1,82%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 4,85x
EV / Sales 2019 4,72x
Capitalization 53 753 M
Duration : Period :
Allergan plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 210 $
Spread / Average Target 32%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Charles Hugh-Jones Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-3.58%53 753
JOHNSON & JOHNSON3.24%387 546
PFIZER18.47%250 618
NOVARTIS6.19%221 937
ROCHE HOLDING LTD.0.39%212 046
MERCK AND COMPANY33.00%194 612